The Comparison of Age-related Macular Degeneration Treatment Trial (CATT) follow-up study found that the initial gains in visual acuity achieved with two anti-vascular endothelial growth factor drugs were lower than those achieved at the end of the 2-year CATT study.
Oxidative stress stemming from a growing accumulation of visual cycle adducts may play an important role in the pathogenesis of AMD, suggest new findings.
Non-invasive photobiomodulation may help dry age-related macular degeneration by causing regression of drusen and improving retinal function with benefits in visual acuity and contrast sensitivity.
Nutritional supplements continue to be a viable prevention strategy for neovascular age-related macular degeneration (AMD), said Emily Chew, MD.
A variety of newer drug delivery approaches may change how patients with age-related macular degeneration are treated.
The topics of special interest to retina specialists during 2015 include optical coherence tomography angiography (OCTA) and screening for retinopathy of prematurity (ROP). Important research is taking place to determine the etiology of angiogenesis, possibly leading to targeting therapies in age-related macular degeneration (AMD), ROP, and diabetic retinopathy.
